AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Acciona S.A.

AGM Information Sep 21, 2018

1777_dva_2018-09-21_64a1ee8f-026d-426e-b85c-2bf79d298a94.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Ananda Developments Plc - Result of General Meeting

PR Newswire

London, September 21

21 September 2018

ANANDA DEVELOPMENTS PLC

(“Ananda” or the “Company”)

Result of General Meeting

The Company is pleased to announce that at the General Meeting held earlier today, the resolution put to shareholders was duly passed.

As a result, the Company has completed its purchase of 15 per cent. of Liberty Herbal Technologies Limited (“LHT”), the 100% owner and developer of hapac®, a patent pending technology for vaping medicinal cannabis.

Melissa Sturgess, Executive Director of Ananda, commented: “We are very excited about the potential of hapac® and look forward to the formal launch of their product in Italy in November, following successful test marketing during 2017.”

The directors of the Company accept responsibility for the contents of this announcement.

--ENDS—

Ananda Developments plc

 

Executive Director

Melissa Sturgess



Investor Relations

Jeremy Sturgess-Smith
+44 (0)739 269 6517









[email protected]
Peterhouse Capital Limited

 

Corporate Finance

Fungai Ndoro

Mark Anwyl



Corporate Broker

Lucy Williams

Duncan Vasey



Celicourt Communications    

Mark Atelme

Joanna Boon
+44 (0)20 7469 0930



















+44 (0)20 7520 9261

Notes to editors

About Ananda Developments PLC

Ananda Developments has been established as a company to invest in the developing market for medical or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the USA, as well as other countries around the world, changing their laws to allow for products containing constituents of Medical Cannabis to be developed, approved and sold.

A copy of the Company’s Admission Document is available at www.anandadevelopments.com and at www.nexexchange.com.

Ananda’s investment strategy is to invest in companies, projects or products that are either progressing medical or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.

http://www.anandadevelopments.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.